Pharmaceuticals News and Research

RSS

Findings open new possibilities for research, testing treatments to combat obesity

Joslin scientists report significant findings about the location, genetic expression and function of human brown adipose tissue and the generation of new BAT cells.

23 Apr 2013

Eating mushrooms can help increase, maintain vitamin D levels, find BUSM researchers

Researchers from Boston University School of Medicine have discovered that eating mushrooms containing Vitamin D2 can be as effective at increasing and maintaining vitamin D levels (25-hydroxyvitamin D) as taking supplemental vitamin D2 or vitamin D3.

23 Apr 2013

Cystic Fibrosis Foundation issues statement on Phase 2 clinical trial of Kalydeco, VX-661

The Cystic Fibrosis Foundation issued the following statement in response to an announcement by Vertex Pharmaceuticals Inc. regarding promising results from a Phase 2 clinical trial of its cystic fibrosis drug Kalydeco in combination with another potential CF therapy, VX-661.

23 Apr 2013

Advaxis to license its ADXS-HPV product candidate to FusionVax

Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced that it has entered into a Memorandum of Understanding (MoU) with FusionVax, Inc. ("FusionVax") setting forth the main terms under which Advaxis will, subject to the entry of a definitive agreement, exclusively license its lead clinical stage product candidate, ADXS-HPV, to FusionVax for Asia.

22 Apr 2013

Synta completes GALAXY-2 trial evaluating ganetespib inhibitor in non-small cell lung cance

Synta Pharmaceuticals Corp. announced today that the first patients have been treated in the randomized GALAXY-2 Phase 3 trial designed to evaluate docetaxel plus ganetespib, its investigational Hsp90 inhibitor, versus docetaxel alone for the second-line treatment of non-small cell lung adenocarcinoma.

22 Apr 2013

Xenon Pharmaceuticalsn receives BIOTECanada's Gold Leaf Company of the Year Award for 2013

Xenon Pharmaceuticals Inc. is pleased to announce that it has been awarded BIOTECanada's Gold Leaf Company of the Year Award for 2013.

22 Apr 2013

Janssen Diabetes Forum: A medical education initiative for management of type 2 diabetes

Launched today in Beerse, the Janssen Diabetes Forum (www.janssendiabetesforum.com) is a novel medical education initiative, which has been developed to contribute to the understanding of the latest developments in the management of type 2 diabetes.

22 Apr 2013

Study indentifies unmet medical need for treatment of patients with chronic pain and dysphagia

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company focused on the development of innovative treatments for chronic pain, today announced the completion of a research study, conducted with an independent market research firm, that identified a significant unmet medical need for improved treatments for patients with chronic pain and dysphagia/odynophagia. In clinical practice, dysphagia is most often defined as difficulty in swallowing and odynophagia is defined as pain upon swallowing.

22 Apr 2013

Phase 2 study of VX-661 and ivacaftor shows significant improvements in lung function among CF patients

Vertex Pharmaceuticals Incorporated today announced data from a Phase 2 study of VX-661 and ivacaftor that showed statistically significant improvements in lung function among adults with cystic fibrosis (CF) who have two copies (homozygous) of the most common mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, known as F508del.

22 Apr 2013

MEDIAN Technologies selected as imaging solutions provider in phase II NSCLC clinical trial

MEDIAN Technologies (ALMDT), a leading medical imaging software solutions developer and a service provider for image interpretation and management in oncology clinical trials, announced today it has been selected as the imaging solutions and services provider in a new phase II clinical trial on Non Small Cell Lung Cancer (NSCLC).

22 Apr 2013

Researchers win Jacob Heskel Gabbay Award in Biotechnology and Medicine

Karl Deisseroth of Stanford University, Gero Miesenb-ck of the University of Oxford and Edward S. Boyden of the Massachusetts Institute of Technology have been awarded Brandeis University's 16th Annual Jacob Heskel Gabbay Award in Biotechnology and Medicine.

22 Apr 2013

Time dwindling to meet IDSA goal of 10 new antibiotics by 2020

Despite the desperate need for new antibiotics to combat increasingly deadly resistant bacteria, the U.S. Food and Drug Administration (FDA) has approved only one new systemic antibiotic since the Infectious Diseases Society of America (IDSA) launched its 10 x '20 Initiative in 2010 - and that drug was approved two and a half years ago.

22 Apr 2013

Sanovas introduces new surgical imaging technology, MicroCam

Sanovas Inc., a life science technology company developing and commercializing the next-generation of micro-invasive diagnostics, devices and drug delivery technologies, announced today the launch of MicroCam™, its OEM "Plug & Play" micro imaging platform for endoscopic device applications.

22 Apr 2013

DecImmune and DSM to develop proprietary antibody therapeutic

DSM Pharmaceutical Products, the custom manufacturing and technology business of Royal DSM (NYSE, Euronext: DSM KON), announced today that it has signed an agreement with venture capital funded DecImmune Therapeutics of Cambridge, Massachusetts, USA.

22 Apr 2013

Study identifies potential drug targets that interfere with cancer metabolism

A massive study analyzing gene expression data from 22 tumor types has identified multiple metabolic expression changes associated with cancer.

22 Apr 2013

Vaccine development expensive but worthy of investment from Congress

During the last three decades, the biopharmaceutical industry has invested significantly in new and improved vaccines, and the collaborative efforts of the [CDC], [the WHO], national governments and industry have led to major progress in addressing global immunization goals and reducing illness and death due to vaccine-preventable diseases.

22 Apr 2013

Bausch + Lomb agrees to commercialize Paragon BioTeck's phenylephrine in US

Bausch + Lomb, the global eye health company and Paragon BioTeck, Inc. today announced that the companies have entered into a license agreement for Bausch + Lomb to commercialize and distribute Paragon's phenylephrine in the United States on an exclusive basis beginning this month.

20 Apr 2013

Civitas Therapeutics reports positive results from Phase 2 study of CVT-301 for Parkinson's disease

Civitas Therapeutics, Inc., a privately-held pharmaceutical company developing transformative therapeutics using the ARCUS respiratory delivery platform, today announced positive topline results from a Phase 2 clinical trial of CVT-301, an inhaled formulation of levodopa (L-dopa).

20 Apr 2013

Research roundup: Community benefits and hospitals' tax-exempt status; Medicaid expansion could benefit people of color; Looking at changes for Medicare

The federal health law requires tax-exempt hospitals to assess and address the needs of the community in which they serve by the end of 2013.

20 Apr 2013

UCSF Professor receives Olof Johnell Science Award for achievements in metabolic bone disease

Harry Genant, Professor Emeritus of the University of California San Francisco, has been named the winner of the International Osteoporosis Foundation's (IOF) first Olof Johnell Science Award.

19 Apr 2013

Pharmaceuticals News and Research

Findings open new possibilities for research, testing treatments to combat obesity

Eating mushrooms can help increase, maintain vitamin D levels, find BUSM researchers

Cystic Fibrosis Foundation issues statement on Phase 2 clinical trial of Kalydeco, VX-661

Advaxis to license its ADXS-HPV product candidate to FusionVax

Synta completes GALAXY-2 trial evaluating ganetespib inhibitor in non-small cell lung cance

Xenon Pharmaceuticalsn receives BIOTECanada's Gold Leaf Company of the Year Award for 2013

Janssen Diabetes Forum: A medical education initiative for management of type 2 diabetes

Study indentifies unmet medical need for treatment of patients with chronic pain and dysphagia

Phase 2 study of VX-661 and ivacaftor shows significant improvements in lung function among CF patients

MEDIAN Technologies selected as imaging solutions provider in phase II NSCLC clinical trial

Researchers win Jacob Heskel Gabbay Award in Biotechnology and Medicine

Time dwindling to meet IDSA goal of 10 new antibiotics by 2020

Sanovas introduces new surgical imaging technology, MicroCam

DecImmune and DSM to develop proprietary antibody therapeutic

Study identifies potential drug targets that interfere with cancer metabolism

Vaccine development expensive but worthy of investment from Congress

Bausch + Lomb agrees to commercialize Paragon BioTeck's phenylephrine in US

Civitas Therapeutics reports positive results from Phase 2 study of CVT-301 for Parkinson's disease

Research roundup: Community benefits and hospitals' tax-exempt status; Medicaid expansion could benefit people of color; Looking at changes for Medicare

UCSF Professor receives Olof Johnell Science Award for achievements in metabolic bone disease

Industry Focus - Biopharma eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence